国药股份
(600511)
| 流通市值：168.05亿 | | | 总市值：229.14亿 |
| 流通股本：5.53亿 | | | 总股本：7.55亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 12,713,002,292.38 | 50,597,449,788.57 | 38,028,539,709.49 | 24,756,503,031.47 |
| 营业收入 | 12,713,002,292.38 | 50,597,449,788.57 | 38,028,539,709.49 | 24,756,503,031.47 |
| 二、营业总成本 | 12,193,672,811.38 | 48,403,886,743.93 | 36,311,068,962.03 | 23,626,002,706.25 |
| 营业成本 | 11,910,228,293.74 | 47,002,226,101.21 | 35,359,757,294.67 | 23,003,398,921.29 |
| 税金及附加 | 26,873,008.77 | 129,311,673.71 | 88,941,449.62 | 57,348,752.67 |
| 销售费用 | 152,279,509.46 | 805,142,288.61 | 582,151,421.92 | 388,692,076.23 |
| 管理费用 | 97,540,087.04 | 461,529,436.04 | 309,744,686.29 | 200,453,847.88 |
| 研发费用 | 13,814,602.47 | 73,707,682.75 | 44,141,243.81 | 28,795,929.7 |
| 财务费用 | -7,062,690.1 | -68,030,438.39 | -73,667,134.28 | -52,686,821.52 |
| 其中:利息费用 | 9,909,832.4 | 33,655,840.77 | 24,266,655.63 | 15,565,603.17 |
| 其中:利息收入 | 17,070,631.25 | 106,782,108.84 | 101,695,428.27 | 73,509,376.89 |
| 加:公允价值变动收益 | - | -18,201,818.94 | - | - |
| 加:投资收益 | 116,029,603.74 | 514,166,266.66 | 316,413,621.02 | 240,328,388.92 |
| 资产处置收益 | -45,796.64 | -186,992.44 | -136,751.71 | -54,073.85 |
| 资产减值损失(新) | -5,876,575.91 | -1,066,320.03 | -6,830,640.93 | -4,052,580.83 |
| 信用减值损失(新) | -31,224,973.26 | -22,820,890.12 | -46,636,044 | -43,368,268.88 |
| 其他收益 | 2,448,012.1 | 11,968,624.68 | 8,980,542.51 | 6,254,954.39 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 600,659,751.03 | 2,677,421,914.45 | 1,989,261,474.35 | 1,329,608,744.97 |
| 加:营业外收入 | 5,297,373.84 | 1,887,414.22 | 1,340,049.16 | 990,469.42 |
| 减:营业外支出 | 79,859.24 | 25,696,937.17 | 24,767,650.56 | 12,765,141.82 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 605,877,265.63 | 2,653,612,391.5 | 1,965,833,872.95 | 1,317,834,072.57 |
| 减:所得税费用 | 120,816,068.97 | 523,831,826.46 | 390,906,697.65 | 254,161,063.8 |
| 六、净利润 | 485,061,196.66 | 2,129,780,565.04 | 1,574,927,175.3 | 1,063,673,008.77 |
| 持续经营净利润 | 485,061,196.66 | 2,129,780,565.04 | 1,574,927,175.3 | 1,063,673,008.77 |
| 归属于母公司股东的净利润 | 459,015,386.52 | 2,000,126,943.49 | 1,481,271,832.85 | 1,000,510,723.1 |
| 少数股东损益 | 26,045,810.14 | 129,653,621.55 | 93,655,342.45 | 63,162,285.67 |
| (一)基本每股收益 | 0.61 | 2.65 | 1.96 | 1.33 |
| (二)稀释每股收益 | 0.61 | 2.65 | 1.96 | 1.33 |
| 八、其他综合收益 | -84,421.65 | -3,461,287.34 | -4,446,206.5 | -8,526,585.89 |
| 归属于母公司股东的其他综合收益 | -84,421.65 | -3,461,287.34 | -4,446,206.5 | -8,526,585.89 |
| 九、综合收益总额 | 484,976,775.01 | 2,126,319,277.7 | 1,570,480,968.8 | 1,055,146,422.88 |
| 归属于母公司股东的综合收益总额 | 458,930,964.87 | 1,996,665,656.15 | 1,476,825,626.35 | 991,984,137.21 |
| 归属于少数股东的综合收益总额 | 26,045,810.14 | 129,653,621.55 | 93,655,342.45 | 63,162,285.67 |
| 公告日期 | 2025-04-25 | 2025-03-20 | 2024-10-24 | 2024-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |